ABVC BioPharma Stock Price, News & Analysis (NASDAQ:ABVC) $1.25 -0.10 (-7.41%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$1.22▼$1.3650-Day Range$0.81▼$2.0252-Week Range$0.67▼$18.70Volume437,472 shsAverage Volume930,199 shsMarket Capitalization$9.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media About ABVC BioPharma Stock (NASDAQ:ABVC)ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.Read More ABVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABVC Stock News HeadlinesDecember 7, 2023 | finance.yahoo.comABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyDecember 5, 2023 | finance.yahoo.comABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsDecember 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 29, 2023 | americanbankingnews.comShort Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Declines By 91.1%November 21, 2023 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNovember 21, 2023 | marketwatch.comABVC BioPharma Shares Rise 11% After U.S. Patent for ADHD TreatmentNovember 21, 2023 | finance.yahoo.comABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNovember 16, 2023 | markets.businessinsider.comABVC BioPharma Enters Into Global LIcensing Agreement With AiBtlDecember 7, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 16, 2023 | finance.yahoo.comABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MNovember 15, 2023 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsNovember 15, 2023 | msn.comABVC BioPharma GAAP EPS of -$0.82, revenue of $0.02MNovember 15, 2023 | finance.yahoo.comABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsOctober 27, 2023 | benzinga.comWhat's Going On With ABVC Biopharma Stock Friday?October 26, 2023 | marketwatch.comHealth Care Down Amid Mixed Earnings -- Health Care RoundupOctober 26, 2023 | benzinga.comWhat In The World Is Going On With ABVC BioPharma Stock?October 26, 2023 | msn.comABVC shares jump after signing licensing deal for CNS drugsOctober 26, 2023 | marketwatch.comABVC Shares More than Triple on Licensing DealOctober 26, 2023 | finance.yahoo.comABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 MillionOctober 10, 2023 | msn.comABVC BioPharma obtains patent for MDD treatment in TaiwanOctober 9, 2023 | markets.businessinsider.comABVC BioPharma Gets Taiwanese Patent For Use Of Polygala Extract For Depressive DisorderOctober 9, 2023 | finance.yahoo.comABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)August 23, 2023 | finance.yahoo.comABVC BioPharma Provides Updates on ADHD Phase IIb Clinical StudyAugust 17, 2023 | markets.businessinsider.comABVC BioPharma Enters Into Agreement To Exchange 20% Stake In Real Estate Property Of ZhonghuiAugust 17, 2023 | finance.yahoo.comABVC Executes Cooperation Agreement for Strategic InvestmentsAugust 10, 2023 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price RequirementAugust 10, 2023 | finance.yahoo.comABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price RequirementSee More Headlines Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABVC CUSIPN/A CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,420,000.00 Net Margins-1,611.23% Pretax Margin-1,493.78% Return on Equity-348.52% Return on Assets-102.42% Debt Debt-to-Equity Ratio0.18 Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$970,000.00 Price / Sales9.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.99 per share Price / Book1.27Miscellaneous Outstanding Shares7,230,000Free Float4,412,000Market Cap$9.11 million OptionableNot Optionable Beta0.46 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Eugene Jiang (Age 37)Chairman & Chief Business Officer Comp: $200kMr. Leeds Chow (Age 34)CFO & Principal Accounting Officer Comp: $130kDr. Tsung-Shann Jiang EMBA (Age 69)Ph.D., Chief Scientific Officer & Director Comp: $200kDr. Uttam Yashwant Patil Ph.D.Chief Executive OfficerKey CompetitorsGT BiopharmaNASDAQ:GTBPAileron TherapeuticsNASDAQ:ALRNImpel PharmaceuticalsNASDAQ:IMPLTrevenaNASDAQ:TRVNFlora GrowthNASDAQ:FLGCView All Competitors ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed in 2023? ABVC BioPharma's stock was trading at $6.25 at the beginning of 2023. Since then, ABVC stock has decreased by 80.0% and is now trading at $1.25. View the best growth stocks for 2023 here. Are investors shorting ABVC BioPharma? ABVC BioPharma saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 87,700 shares, a decrease of 91.1% from the October 31st total of 984,400 shares. Based on an average daily volume of 2,430,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the shares of the company are sold short. View ABVC BioPharma's Short Interest. When is ABVC BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our ABVC earnings forecast. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.90) by $0.40. The firm had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.03 million. ABVC BioPharma had a negative trailing twelve-month return on equity of 348.52% and a negative net margin of 1,611.23%. When did ABVC BioPharma's stock split? ABVC BioPharma's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? (ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ABVC) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.